

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: [Riggins, Cindy](#); [narin.ahmed@novartis.com](#)
Subject: BL 125646 Clinical Information Request
Date: Friday, August 11, 2017 1:23:01 PM
Attachments: [image001.png](#)

Good afternoon,

Please provide a complete list of terms that were used to assess the Group of cytokine release syndrome for B2202. Please e-mail me a response by 4 pm today, August 11, 2017 and follow-up by submitting the information as a formal amendment to the BLA.

Thank you,

Erica Giordano

Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8298
Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."